Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Tomoxetine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel carbonyl reductase mutant enables high-purity chiral intermediate synthesis with reduced solvent waste and cost for pharmaceutical supply chains.
Advanced chiral resolution technology for high-purity pharmaceutical intermediates. Discover cost-effective manufacturing solutions for Tomoxetine and Fluoxetine precursors.
Novel patent CN106916074A offers high-purity Tomoxetine Hydrochloride synthesis with recyclable solvents and reduced environmental impact for reliable supply.
Patent CN1950326A details a high-yield optical resolution and recycling process for atomoxetine intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112708641A discloses a high-efficiency chemo-enzymatic route for tomoxetine. Achieves >99.9% ee and high substrate loading for cost-effective manufacturing.
Patent CN104805142A enables high-purity Tomoxetine via enzyme catalysis. Reduces cost and improves supply chain reliability for pharmaceutical intermediates manufacturing.